Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 67 articles: HTML format Text format

Single Articles

February 2012
1. WAN X , Liu J, Lu JF, Tzelepi V, et al
   Activation of beta-Catenin Signaling in Androgen Receptor-Negative Prostate Cancer Cells.
   Clin Cancer Res. 2012;18:726-36.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2012
2. LANGE T , Ullrich S, Muller I, Nentwich MF, et al
   Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of beta(1,6)-branched Oligosaccharides as a Marker of Tumor Progression.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
3. TZELEPI V , Zhang J, Lu JF, Kleb BN, et al
   Modeling Lethal Prostate Cancer Variant with Small Cell Carcinoma Features.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
4. FRASER M , Zhao H, Luoto KR, Lundin C, et al
   PTEN Deletion in Prostate Cancer Cells Does Not Associate With Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. LOCKE JA , Zafarana G, Ishkanian AS, Milosevic M, et al
   NKX3.1 Haploinsufficiency is Prognostic for Prostate Cancer Relapse Following Surgery or Image-Guided Radiotherapy.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. SCHER HI , Nasso SF, Rubin EH, Simon R, et al
   Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
   Clin Cancer Res. 2011;17:6634-40.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
7. CHEN Y , Pullambhatla M, Byun Y, Foss CA, et al
   2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate Cancer.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. CONTRACTOR KB , Challapalli A, Barwick T, Winkler M, et al
   Use of [11C]choline PET-CT as a non invasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
9. SONPAVDE G , Thompson TC, Jain RK, Ayala GE, et al
   GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   August 2011
10. LOTAN T , Gurel B, Sutcliffe S, Esopi D, et al
    PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. CHEN L , Mooso B, Jathal MK, Madhav A, et al
    Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. MOSTAGHEL EA , Marck B, Plymate S, Vessella RL, et al
    Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
13. MINNER S , Enodien M, Sirma H, Luebke AM, et al
    ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. SAAD F , Hotte S, North S, Eigl B, et al
    Randomized Phase 2 Trial of Custirsen (OGX-011) with Docetaxel or Mitoxantrone in Patients with Metastatic Castrate-Resistant Prostate Cancer: CUOG Trial P06c.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
15. SIDDIQUE HR , Mishra SK, Karnes RJ, Saleem M, et al
    Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. MOHLER JL , Titus MA, Wilson EM
    Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. MAY KF JR , Gulley JL, Drake CG, Dranoff G, et al
    Prostate Cancer Immunotherapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. DANILA DC , Fleisher M, Scher HI
    Circulating tumor cells as biomarkers in prostate cancer.
    Clin Cancer Res. 2011;17:3903-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. MADAN RA , Pal SK, Sartor O, Dahut WL, et al
    Overcoming chemotherapy resistance in prostate cancer.
    Clin Cancer Res. 2011;17:3892-902.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. GULLEY JL , Drake CG
    Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
    Clin Cancer Res. 2011;17:3884-91.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. MASSARD C , Fizazi K
    Targeting continued androgen receptor signaling in prostate cancer.
    Clin Cancer Res. 2011;17:3876-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. ATTARD G , de Bono JS
    Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
    Clin Cancer Res. 2011;17:3867-75.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. BATES SE
    Prostate cancer: score one for validated targets.
    Clin Cancer Res. 2011;17:3866.
    PubMed     Text format     Related articles   
    
    
    
    
24. RYAN CJ , Shah SK, Efstathiou E, Smith MR, et al
    Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
25. YU W , Feng S, Dakhova O, Creighton CJ, et al
    FGFR-4 Arg388 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. LEE P , Li Y, Ligr M, McCarron J, et al
    Natura-Alpha Targets Forkhead Box M1 and Inhibits Androgen-Dependent and -Independent Prostate Cancer Growth and Invasion.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. JENSEN AR , David SY, Liao C, Dai J, et al
    Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
    Clin Cancer Res. 2011;17:3112-22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. KIM YJ , Yoon HY, Kim SK, Kim YW, et al
    EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-based DNA Methylation and Expression Profiling.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. BEER TM , Bernstein GT, Corman JM, Glode M, et al
    RANDOMIZED TRIAL OF AUTOLOGOUS CELLULAR IMMUNOTHERAPY WITH SIPULEUCEL-T IN ANDROGEN DEPENDENT PROSTATE CANCER.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. MEHRA R , Kumar-Sinha C, Lonigro RJ, Shankar S, et al
    Characterization of bone metastases from rapid autopsies of prostate cancer patients.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. ATTARD G , Crespo M, Lim AC, Pope L, et al
    Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter.
    Clin Cancer Res. 2011;17:3048-9.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
32. SINGH PP , Joshi S, Russell PJ, Verma ND, et al
    Molecular chemotherapy and Chemotherapy: A new front against late stage hormone refractory prostate cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
33. SOUVATZOGLOU M , Weirich G, Schwarzenboeck S, Maurer T, et al
    The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. CHEEVER MA , Higano C
    PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA Approved Therapeutic Cancer Vaccine.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
35. ATTARD G , Richards J, de Bono JS
    Targeting the androgen receptor signaling pathway in metastatic prostate cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. MORGAN R , Boxall A, Bhatt A, Bailey M, et al
    Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer.
    Clin Cancer Res. 2011;17:1090-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. MORTEZAVI A , Hermanns T, Seifert HH, Baumgartner MK, et al
    KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Clin Cancer Res. 2011;17:1111-21.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
38. ZHAU HE , He H, Wang CY, Zayzafoon M, et al
    Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. LAMOUREUX F , Thomas C, Yin MJ, Kuruma H, et al
    A novel HSP90 inhibitor delays castrate resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. AHN J , Kibel AS, Park JY, Rebbeck TR, et al
    Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. MOHAMEDALI KA , Li ZG, Starbuck MW, Wan X, et al
    Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
42. RIGAMONTI N , Capuano G, Ricupito A, Jachetti E, et al
    Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
43. FROMONT G , Validire P, Prapotnich D, Rozet F, et al
    PATHOLOGICAL REASSESSMENT OF PROSTATE CANCER SURGICAL SPECIMENS BEFORE MOLECULAR RETROSPECTIVE STUDIES.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. KARBACH J , Neumann A, Atmaca A, Wahle C, et al
    Efficient in-vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. SAINI S , Majid S, Yamamura S, Tabatabai ZL, et al
    Regulatory role of miR-203 in prostate cancer progression and metastasis.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. SORRENTINO C , Musiani P, Pompa P, Cipollone G, et al
    Androgen Deprivation Boosts Prostatic Infiltration of Cytotoxic and Regulatory T Lymphocytes and Has No Effect on Disease-Free Survival in Prostate Cancer Patients.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. BAO BY , Pao JB, Huang CN, Pu YS, et al
    Polymorphisms inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. WEI JJ , Wu X, Peng Y, Shi G, et al
    Regulation of HMGA1 expression by microRNA296 affects prostate cancer growth and invasion.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. SUN T , Lee GS, Oh WK, Freedman ML, et al
    Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. RATHKOPF D , Liu G, Carducci MA, Eisenberger MA, et al
    Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. D'ANTONIO KB , Schultz L, Albadine R, Mondul AM, et al
    Decreased expression of cyr61 is associated with prostate cancer recurrence after surgical treatment.
    Clin Cancer Res. 2010;16:5908-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. DUBROVSKA A , Elliott J, Salamone RJ, Kim S, et al
    Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
    Clin Cancer Res. 2010;16:5692-702.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
53. STEIN WD , Gulley J, Schlom J, Madan RA, et al
    Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. CHANG G , Xu S, Dhir R, Chandran U, et al
    Hypoexpression and Epigenetic Regulation of Candidate Tumor Suppressor Gene CADM-2 in Human Prostate Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
55. KEIZMAN D , Zahurak M, Sinibaldi V, Carducci M, et al
    Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. MEIRELLES GS , Schoder H, Ravizzini GC, Gonen M, et al
    PROGNOSTIC VALUE OF BASELINE [18F] FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY AND 99mTc-MDP BONE SCAN IN PROGRESSING METASTATIC PROSTATE CANCER.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. RISK MC , Knudsen BS, Coleman I, Dumpit R, et al
    Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
58. KANG BH , Siegelin MD, Plescia J, Raskett CM, et al
    Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. SUN T , Lee GS, Oh WK, Pomerantz M, et al
    Single-nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. LIU SV , Schally AV, Hawes D, Xiong S, et al
    Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.
    Clin Cancer Res. 2010;16:4675-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. RUSSELL M , Liu Q, Fatatis A
    TARGETING THE ALPHA RECEPTOR FOR PLATELET-DERIVED-GROWTH FACTOR AS A PRIMARY OR COMBINATION THERAPY IN A PRECLINICAL MODEL OF PROSTATE CANCER SKELETAL METASTASIS.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
62. VICKERS AJ , Cronin AM, Roobol MJ, Hugosson J, et al
    The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
63. YAMAOKA M , Hara T, Kusaka M
    Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. MAYER EL , Krop IE
    Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
    Clin Cancer Res. 2010;16:3526-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. KWABI-ADDO B , Wang S, Chung W, Jelinek J, et al
    Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men.
    Clin Cancer Res. 2010;16:3539-47.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. SAEKI N , Gu J, Yoshida T, Wu X, et al
    Prostate stem cell antigen: a Jekyll and Hyde molecule?
    Clin Cancer Res. 2010;16:3533-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
67. PILI R , Rosenthal MA, Mainwaring PN, Van Hazel G, et al
    Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
    Clin Cancer Res. 2010;16:2906-14.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: